Back to Search
Start Over
Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10
- Source :
- GlobeNewswire. July 25, 2019
- Publication Year :
- 2019
-
Abstract
- DUBLIN, Ireland and CAMBRIDGE, Jul 25, 2019 (GLOBE NEWSWIRE via COMTEX) -- Expect first patient dosing in second half of 2019 Allergan plc (NYSE: AGN), a leading global pharmaceutical company, [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.594433121